2006
Reinfection and relapse in early Lyme disease.
KRAUSE PJ, FOLEY DT, BURKE GS, Christianson D, Closter L, Spielman A, _ _. Reinfection and relapse in early Lyme disease. American Journal Of Tropical Medicine And Hygiene 2006, 75: 1090-4. PMID: 17172372, DOI: 10.4269/ajtmh.2006.75.1090.Peer-Reviewed Original ResearchConceptsEarly Lyme diseaseRecurrent episodesLyme diseaseErythema migransStandard antibiotic therapyInitial rashPrompt administrationAntibiotic therapyClinical manifestationsPrevent relapsePersistent infectionBody sitesDiseaseSequential episodesSpecific antibodiesEndemic sitesEpisodesReinfectionRelapseDetectable levelsFrequent contactVector ticksYearsRashSerology
2001
Safety and Immunogenicity of a Recombinant Borrelia burgdorferi Outer Surface Protein A Vaccine Against Lyme Disease in Healthy Children and Adolescents: A Randomized Controlled Trial
Sikand V, Halsey N, Krause P, Sood S, Geller R, Van Hoecke C, Buscarino C, Parenti D. Safety and Immunogenicity of a Recombinant Borrelia burgdorferi Outer Surface Protein A Vaccine Against Lyme Disease in Healthy Children and Adolescents: A Randomized Controlled Trial. Pediatrics 2001, 108: 123-128. PMID: 11433064, DOI: 10.1542/peds.108.1.123.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAntigens, SurfaceArthralgiaBacterial Outer Membrane ProteinsBacterial VaccinesBorrelia burgdorferi GroupChildChild, PreschoolEdemaErythemaExanthemaFatigueFemaleFeverHeadacheHumansImmunoglobulin GIncidenceInjectionsLipoproteinsLyme DiseaseLyme Disease VaccinesMalePainSeverity of Illness IndexTime FactorsUnited StatesConceptsLocal injection site reactionsInjection site reactionsYears of ageMonth 13LD vaccineVaccine recipientsSite reactionsHealthy childrenEfficacy studiesChildren 4Placebo-controlled clinical trialUnsolicited adverse eventsFlu-like symptomsLyme disease vaccineHigher immune responseLyme endemic areasOuter Surface ProteinsAdolescents 15 yearsIgG GMTPlacebo recipientsReactogenicity dataAdverse eventsControlled TrialsMonth 6Immunogenicity data